Activating the immune system at the site of a tumor can recruit and stimulate immune cells to destroy tumor cells.

Important insight into a vexing problem that has plagued millions who have not fully recovered their sense of smell after COVID-19.

The 'game-changing' treatment used different human immune cells known as natural killer (NK) cells—with dramatic results.

Treatment for the condition has improved in recent years — and a new Edith Cowan study has found how to make it even more effective.

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor.

In the new JEM study, teams used a computer-based screening approach to identify a drug, named C26, that activates NR2F1.

A trial in people with high hereditary risk of a wide range of cancers has shown a major preventive effect from resistant starches.

Researchers have developed a synthetic molecule that combines a tumor-targeting agent with another molecule that triggers immune activation.

Treatment for lung cancer has improved in recent years — and a new Edith Cowan University study has found how to make it even more effective

Albert Einstein College of Medicine research team used different human immune cells known as natural killer (NK) cells with dramatic results

T cells snuggle up to targeted diseased cells and form an intimate junction between the two, called the ‘cytotoxic immunological synapse’.

Researchers developed a new synthetic molecule that combines a tumor-targeting agent with another molecule that triggers immune activation.

Researchers have developed an experimental vaccine that shows significant promise in preventing rheumatoid arthritis which cannot be cured.

DNA from victims and survivors of the Black Death pandemic has identified key genetic differences that determined who lived and who died.

A new therapeutic approach prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state.

These findings provide a promising basis for developing effective medications for glioblastoma, an aggressive, and thus far incurable cancer

Researchers have developed a new synthetic molecule that combines a tumor-targeting agent with another molecule that triggers immunity.

A new mechanism that slows down and may even prevent the natural ageing of immune cells – one of the nine ‘hallmarks of ageing’.

As a part of our immune defences, cytotoxic T cells – or killer T cells – seek out and destroy cells that are infected or cancerous.

Scientists have been searching for an antibody that would be broadly neutralizing — able to fight off any viral variant that might emerge.